Journal
DRUG DISCOVERY TODAY
Volume 15, Issue 1-2, Pages 71-77Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2008.12.010
Keywords
-
Categories
Funding
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI084551] Funding Source: NIH RePORTER
- NIAID NIH HHS [R01 AI084551] Funding Source: Medline
Ask authors/readers for more resources
Rapid growth in the development of new tools and advances in molecular immunology has led to a class of drugs called biologics. While effective, these therapies are costly, typically require continuous administration and often have serious side effects. This review focuses on current therapies and the need for a new class of therapies. A novel class of drugs able to induce and maintain tolerance will be paralleled with the notion that combination therapy appropriately tailored to patient subpopulations may hold the promise of less costly and more effective therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available